Skip to Content

'
Muzaffar H. Qazilbash, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

1. Stem Cell Transplantation for Multiple Myeloma 

2. Cancer Vaccines

3. # 2 Immunotherapy

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: Unit 423
Houston, TX 77030
Room Number: FC5.2006
Email: mqazilba@mdanderson.org

Education & Training

Degree-Granting Education

1987 University of Karachi, School of Medicine, Karachi, Pakistan, Pakistan, MD, MD

Postgraduate Training

7/1992-6/1995 Fellow, Hematology and Oncology, Dr. C. E. Dunbar, National Heart Lung and Blood Institute and National Cancer Institute National Institutes of Health, Bethesda, MD
7/1991-6/1992 Clinical Residency, The University of Connecticut, Farmington, CT
7/1989-6/1991 PGY-Y and 2, Internal Medicine Dr. H. V. Barnes, Wright State University, Dayton, OH

Experience/Service

Institutional Committee Activities

Co-Director, Stem Cell Transplantation Fellowship Program, 9/2008-present
Associate Director, Hematology/Oncology Fellowship Program, 8/2008-1/2010

Selected Publications

Peer-Reviewed Original Research Articles
1. Qazilbash MH, Walsh CE, Russell SM, Noguchi M, Mann MM, Leonard WJ, Liu JM. Retroviral vector for gene therapy of X-linked severe combined immunodeficiency syndrome. J Hematother 4:91-8, 4/1995. PMID: 7633846.
2. Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type. Gene Ther 4:675-82, 7/1997. PMID: 9282168.
3. Qazilbash MH, Liu JM, Vlachos A, Fruchtman S, Messner H, Zipursky A, Alter BP, Young NS. A new syndrome of familial aplastic anemia and chronic liver disease. Acta Haematol 97:164-7, 1997. PMID: 9066711.
4. Paul D, Qazilbash MH, Song K, Xu H, Sinha BK, Liu J, Cowan KH. Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12). Cancer Gene Ther 7:308-15, 2/2000. PMID: 10770641.
5. Qazilbash MH, Devetten MP, Abraham J, Lynch JP, Beall CL, Auber M, Weisenborn R, Bunner P, Ericson SG. High-dose therapy and autologous stem cell transplantation in relapsed and refractory Hodgkin's disease: outcome based on a prognostic model. Acta Haematol 110:173-8, 2003. PMID: 14663160.
6. Qazilbash MH, Devetten MP, Abraham J, Lynch JP, Beall CL, Weisenborn R, Bunner P, Ericson SG. Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Acta Haematol 109:119-23, 2003. PMID: 12714820.
7. Qazilbash MH, Giralt SA, Champlin RE. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 18:703-13, xi, 6/2004. PMID: 15271401.
8. Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, Champlin R. Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol 80:43-5, 9/2005. PMID: 16138357.
9. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 106:1084-9, 3/2006. PMID: 16456814.
10. Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 47:1360-4, 7/2006. PMID: 16923569.
11. Qazilbash MH, Ueno N , Hosing C , de Lima M , Cortes J , Massaro A , Rivera Z, Deavers M , Adachi JA, Champlin RE. Strongyloidiasis after Unrelated Non-myeloablative Allogeneic Stem Cell Transplantation. Bone Marrow Transplant 38(5):393-4, 2006. PMID: 16845427.
12. Qazilbash MH, Saliba, R., Hosing, C., de Lima, M., Couriel, D., Mendoza, F., Qureshi, S. R., Weber, D. M., Wang, M., Flosser, T., Kebriaei, P., Popat, U., Alousi, A. M., Champlin, R., Giralt, S. Autologous Stem Cell Transplantation is Safe and Feasible in Elderly Patients with Multiple Myeloma. Bone Marrow Transplant 39(5):279-83, 3/2007. e-Pub 1/2007. PMID: 17262062.
13. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 13(9):1066-72, 9/2007. e-Pub 7/2007. PMID: 17697969.
14. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial. Biol Blood Marrow Transplant 14(12):1401-7, 12/2008. PMID: 19041063.
15. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-6, 7/2009. PMID: 19539212.
16. Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-36, 3/2010. PMID: 19668237.
17. de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima M. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1094-9, 9/2009. PMID: 19660722.
18. Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, Hosing C, Giralt SA, de Lima MJ, Popat UR, Yusuf SW, Champlin RE. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction. Biol Blood Marrow Transplant 15(10):1265-70, 10/2009. e-Pub 8/2009. PMID: 19747634.
19. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 16(8):1122-1129, 8/2010. e-Pub 2/2010. PMID: 20178853.
20. Kazmi SM, Saliba RM, Donato M, Wang M, Hosing C, Qureshi S, Anderlini P, Popat U, Champlin RE, Giralt SA, Qazilbash MH. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant 46(4):510-5, 4/2011. e-Pub 6/28/2010. PMID: 20581887.
21. Sharma M, Qureshi SR, Champlin RE, Popat U, Giralt S, Qazilbash MH. The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. Am J Hematol 85(7):502-4, 7/2010. PMID: 20575022.
22. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biol Blood Marrow Transplant 17(3):412-20, 3/2011. e-Pub 7/30/2010. PMID: 20674757.
23. Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y, Wieder ED, Clise-Dwyer K, Alatrash G, Mj Y, Munsell MF, Lu S, Qazilbash MH, Molldrem JJ. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 12(8):1056-62, 12/2010. e-Pub 8/24/2010. PMID: 20735170.
24. Anderlini P, Acholonu SA, Okoroji GJ, Bassett RE, Shpall EJ, Qazilbash MH, Popat UR, Worth LL, Giralt SA, Champlin RE. Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia. Leuk Lymphoma 52(1):137-41, 1/2011. PMID: 20939697.
25. Bashir Q, Langford LA, Parmar S, Champlin RE, Qazilbash MH. Primary Systemic Amyloid Light Chain Amyloidosis Decompensating After Filgrastim-Induced Mobilization and Stem-Cell Collection. J Clin Oncol 29(4):e79-80, 2/1/2011. e-Pub 11/8/2010. PMID: 21060030.
26. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth Through Eighth Decades of Life. Biol Blood Marrow Transplant. e-Pub 2/18/2011. PMID: 21338705.
27. Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant. e-Pub 3/21/2011. PMID: 21423123.
28. Hosing C, Smith V, Rhodes B, Walters K, Thompson R, Qazilbash M, Khouri I, de Lima M, Balzer RJ, McMannis J, Champlin R, Giralt S, Popat U. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion. e-Pub 5/16/2011. PMID: 21575005.
29. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplantation in patients aged =70 years with multiple myeloma. Leuk Lymphoma. e-Pub 7/23/2011. PMID: 21780997.
30. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation with Sorafenib. Biol Blood Marrow Transplant. e-Pub 7/15/2011. PMID: 21767516.
31. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. e-Pub 9/1/2011. PMID: 21887685.

Book Chapters
1. Qazilbash MH. Peptide Vaccines for AML. In: Immunotherapy and Gene Therapy. Springer Science. In Press.
2. Qazilbash MH, Cortes JE. Myeloid Leukemia. In: Bethesda Handbook of Clinical Oncology, Second. Ed(s) Abraham J, Gulley JL, Allegra C. Lippincott Williams & Wilkins: Baltimore, 331, 2005. PMID: 0787-5116-0.

Last updated: 9/8/2011